Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2018

Open Access 01-03-2018 | Guidelines

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype

Authors: Paul Adams, Albert Altes, Pierre Brissot, Barbara Butzeck, Ioav Cabantchik, Rodolfo Cançado, Sonia Distante, Patricia Evans, Robert Evans, Tomas Ganz, Domenico Girelli, Rolf Hultcrantz, Gordon McLaren, Ben Marris, Nils Milman, Elizabeta Nemeth, Peter Nielsen, Brigitte Pineau, Alberto Piperno, Graça Porto, Dianne Prince, John Ryan, Mayka Sanchez, Paulo Santos, Dorine Swinkels, Emerência Teixeira, Ketil Toska, Annick Vanclooster, Desley White, Contributors and Hemochromatosis International Taskforce

Published in: Hepatology International | Issue 2/2018

Login to get access

Abstract

Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training. This final version was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.
Literature
1.
Vanclooster A, et al. The quality of hereditary haemochromatosis guidelines: a comparative analysis. Clin Res Hepatol Gastroenterol 2015;39(2):205–214.CrossRefPubMed
2.
European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53(1):3–22.CrossRef
3.
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(1):328–343.CrossRefPubMedPubMedCentral
4.
Bardou-Jacquet E, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol 2015;62(3):682–689.CrossRefPubMed
5.
Ong SY, et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematol 2017;4(12):607–614.CrossRef
6.
Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313(20):1256–1262.CrossRefPubMed
7.
Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol 2016;10(3):359–370.CrossRefPubMed
8.
De Buck E, Pauwels NS, Dieltjens T, Compernolle V, Vandekerckhove P. Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review. J Hepatol 2012;57(5):1126–1134.CrossRefPubMed
9.
Liu J, Sun B, Yin H, Liu S. Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine (Baltimore) 2016;95(14):e3150.CrossRef
Metadata
Title
Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
Authors
Paul Adams
Albert Altes
Pierre Brissot
Barbara Butzeck
Ioav Cabantchik
Rodolfo Cançado
Sonia Distante
Patricia Evans
Robert Evans
Tomas Ganz
Domenico Girelli
Rolf Hultcrantz
Gordon McLaren
Ben Marris
Nils Milman
Elizabeta Nemeth
Peter Nielsen
Brigitte Pineau
Alberto Piperno
Graça Porto
Dianne Prince
John Ryan
Mayka Sanchez
Paulo Santos
Dorine Swinkels
Emerência Teixeira
Ketil Toska
Annick Vanclooster
Desley White
Contributors and Hemochromatosis International Taskforce
Publication date
01-03-2018
Publisher
Springer India
Published in
Hepatology International / Issue 2/2018
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-018-9855-0

Other articles of this Issue 2/2018

Hepatology International 2/2018 Go to the issue

Editorial

Prevention of mother-to-child transmission: the key of hepatitis B virus elimination

Original Article

Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis

Original Article

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

Original Article

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

Review Article

Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

Original Article

Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits